Eli Lilly forges on with PhIII evacetrapib trial; Biogen inks Parkinson's discovery pact; Soon-Shiong's NantKwest heads for IPO;

@FierceBiotech: Allergan bags NMDA depression drugs in $560M-plus Naurex buyout. News | Follow @FierceBiotech

@JohnCFierce: The China stock landslide is back on. More from Reuters | Follow @JohnCFierce

@DamianFierce: I kinda forgot this hadn't already happened, tbh. Aegerion release/Article | Follow @DamianFierce

> Eli Lilly ($LLY) says that it will push ahead to the end on its Phase III study of evacetrapib, a CETP inhibitor that hopes to succeed where other giants have failed. Lilly says that the ACCELERATE study data monitoring committee recommended continuing the study following a futility analysis. The last patient visit in the study is expected in July 2016. Investigators recruited roughly 12,000 patients for this trial. Release

> Three days after falling off a cliff on Wall Street, Biogen ($BIIB) is back with a discovery deal with the Parkinson's Institute and Clinical Center. Release

> Patrick Soon-Shiong's NantKwest is slated to price its IPO shares these evening. The company designed the IPO to raise about $150 million. If all goes as planned, the company will have a $2.2 billion market cap. Story

> Brisbane, CA-based Aimmune Therapeutics set a range of $14 to $16 a share on its IPO, with plans to sell 8.3 million shares. Story

> Germany's leon nanodrugs raised €18.5 million ($20.5 million) in Series A cash to advance its efforts to reformulate small-molecule and protein-based therapeutics using its in-house platform. More

> Samsung's biosimilars joint venture is planning to go public in the U.S. next year, Reuters reports. News

Medical Device News

@FierceMedDev: ICYMI: Oxford Performance Materials gets FDA nod for 3-D printed spinal implant. Report | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: Shire CEO: We're prepared to wait for the right deal. Article | Follow @EmilyWFierce

> Varian signs $124M deal with U.K.'s NHS for ProBeam cancer therapy. News

> Sorin stock plummets as Italian feds seek to block its merger with Cyberonics. Story

> Docs dole out recs for reducing fetal ultrasound procedures in the U.S. More

Pharma News

@FiercePharma: Harvard scientists link pesticides with bee losses. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Lupin lands its first US manufacturing site with $880M deal for GAVIS, 6-year-old NJ firm. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: UnitedHealth uses newfound scale to negotiate pay-for-performance deals. Article | Follow @CarlyHFierce

> Amgen wins new myeloma nod for blockbuster hopeful Kyprolis. News

> AstraZeneca snags $300M from Sanofi for rare cancer med amid cash-generating deal spree. Story

> Forget Mylan: Teva inks $40B-plus pact for Allergan's generics biz. Article

Animal Health News

> Animal health drives double-digit growth at Abaxis. Report

> Harvard scientists link pesticides with bee losses. Item

> H.J. Baker breaks ground on multimillion-dollar facility near KC animal health corridor. More

> USDA speeds development of bird flu vaccine as fears of revived virus mount. Article

> Aratana predicts full launch of two lymphoma drugs for dogs in late 2016. Story

Biotech IT News

> SynBio startup Ginkgo Bioworks lands $45M to fuel push into pharma. More

> PCORI board signs off on $142.5M investment to scale up health data network. Story

> BGI CEO steps down to escalate interest in artificial intelligence. Article

> Deep Genomics sets up shop to marry deep learning and genomics. Item

> Oxford Nanopore raises $109M ahead of key period for its sequencing technology. Report

Pharma Marketing News

> Sanofi draws a $14,600 line in the sand for Praluent payer fight. Report

> Spotlight-savvy Kim Kardashian adds Duchesnay med to her talking points. Story

> Will marketing make the difference in approval of Sprout's 'pink pill' for women? News

> J&J's Stelara may be under fire in psoriasis, but it's positioned to score elsewhere. More

> I'll prescribe it if you do: Prescribers susceptible to peer pressure, study finds. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.